Compare Amgen, Inc. (AMGN) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Teladoc Health Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Teladoc Health Inc trades at $9.22 (market cap $1.68B). The key difference: Amgen, Inc. is far larger — about 116.7× Teladoc Health Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| AMGN | TDOC | |
|---|---|---|
Market Cap | $196.12B | $1.68B |
Sector | Health | Health |
52-Week High | $388.16 | $9.52 |
52-Week Low | $271.18 | $4.47 |
Enterprise Value | $241.41B | $1.96B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Teladoc Health (TDOC) trades at $9.28, up 0.76% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.53B in 2025 with a net loss of $200.32M, though losses are narrowing year-over-year. Recent news highlights expansion through the Walmart partnership and ongoing cost-cutting initiatives. Valuation ratios show a P/S of 0.65 and EV/EBITDA of 9.14, suggesting potential undervaluation relative to sales.
Outlook remains cautious despite improving fundamentals; analyst consensus is mixed with 35.7% buy ratings but a $8.75 price target below current levels. Key risks include persistent net losses, competitive pressures in telehealth, and high debt levels. The stock's trajectory hinges on achieving profitability and sustaining growth amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
